Ticker News
$AIM News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
AIM wins European & UK patents for Ampligen in Long COVID through 2041
AIM ImmunoTech announced patents in multiple European countries and the U.K. covering use of Ampligen (tdsRNA) to treat Long COVID, with protection expected through June 2041 after the nine‑month opposition period closed with no challenges; claims include specific dosing regimens and intranasal, intravenous and inhalation delivery. The company says the grants expand its global Ampligen IP estate and complement a recently issued U.S. patent for Ampligen+pembrolizumab, and cites >1,200 patients and 100,000+ doses of clinical experience with favorable safety.
AIM ImmunoTech wins U.S. patent for Ampligen+pembrolizumab combo, protection through Dec 2039
The USPTO granted AIM ImmunoTech a U.S. patent covering use of rintatolimod (Ampligen) in combination with pembrolizumab for treating cancer, with the broadest claim covering combinations that produce greater-than-additive anti-cancer effects; the patent expires December 20, 2039. The patent names multiple cancers including pancreatic (AIM's late-stage focus) and complements existing U.S., Netherlands and Japanese patents on Ampligen+PD-1/PD-L1 combinations, strengthening AIM's oncology IP estate, but the release contains no new clinical efficacy or regulatory data.
AIM CEO urges military biodefense use of Ampligen as broad-spectrum antiviral
AIM ImmunoTech CEO Thomas K. Equels published an op-ed arguing that biodefense should be treated as military force protection and highlighted Ampligen (rintatolimod) as a candidate broad‐spectrum prophylactic/early‐onset antiviral. The company cites government‐funded preclinical work (USAMRIID, reported in Antiviral Research) showing a rintatolimod‐treated mouse cohort had 100% survival vs 100% mortality in controls for a lethal Ebola model and says it is seeking government support for further evaluation and potential force‐protection pathways.
AIM completes enrollment and dosing in Phase 2 pancreatic cancer trial; DURIPANC data expected Q1/Q3 2027
AIM ImmunoTech (AIM) completed enrollment and dosing in the Phase 2 DURIPANC study of Ampligen plus durvalumab in metastatic pancreatic cancer and says it expects clinical benefit data in Q1 2027 and overall survival data in Q3 2027. The company engaged Thermo Fisher PPD to support Phase 3 design, reported $9.9M cash at June 30, 2026 and regained NYSE American compliance, but no efficacy readouts have yet been reported.
AIM ends ATM with Maxim; no further ATM sales after Aug 15, 2026
AIM IMMUNOTECH INC. filed SEC Form 8-K. AIM ImmunoTech notified Maxim of mutual termination of its Equity Distribution (ATM) Agreement, effective August 15, 2026, meaning the company cannot sell additional common shares under that ATM after that date. From April 1, 2025 through July 31, 2026 the company sold 3,200,736 shares for aggregate gross proceeds of approximately $2.8M and says there are no termination penalties.
AIM says final patient dosed early in Phase 2 DURIPANC; topline expected Q1 2027
AIM ImmunoTech (AIM) announced the final subject received their last dose in the investigator-initiated, single-center Phase 2 DURIPANC study of Ampligen + AstraZeneca’s durvalumab for metastatic pancreatic cancer ahead of schedule; analysis of the primary endpoint (Clinical Benefit Rate at 24 weeks) is set to begin in December 2026 with topline results expected in Q1 2027 and an overall survival analysis due June 2027. AIM highlighted an exploratory Named Patient Program where Ampligen monotherapy showed a median OS of 34.8 vs 12.5 months versus historical controls in an NLR<4.5 biomarker subset and said DURIPANC’s immune profiling could inform a pivotal Phase 3 design.
AIM CEO: DURIPANC Phase 2 enrollment/dosing complete; encouraging interim signals for Ampligen
AIM ImmunoTech released a CEO Corner in which CEO Thomas Equels said the DURIPANC Phase 2 trial of Ampligen (rintatolimod) plus AstraZeneca’s durvalumab has completed patient enrollment and dosing and has shown encouraging interim clinical observations with continued favorable safety. The company said Phase 3 planning is underway and highlighted collaborations with AstraZeneca and Erasmus Medical Center and IP expansion, but provided no primary endpoint data or timelines and emphasized the statements are preliminary and forward‐looking.
AIM (AIM) to Present at Webull Corporate Connect Webinar on June 24
AIM ImmunoTech (NYSE: AIM) will present in the Webull Corporate Connect Webinar on June 24, 2026; CEO Thomas Equels is scheduled to speak from 2:40–3:00 PM ET. The appearance gives AIM near-term retail visibility to Webull’s ~27 million registered users, but the announcement does not include any new clinical, financial, or regulatory data.
AIM doses final patient in Phase 2 DURIPANC pancreatic cancer trial; CBR readout expected Dec 2026
AIM ImmunoTech reported the final subject has received the first dose in the Phase 2 DURIPANC study testing Ampligen (rintatolimod) with AstraZeneca's Imfinzi in metastatic pancreatic cancer, triggering a primary endpoint Clinical Benefit Rate (CBR) analysis expected to begin December 2026 and topline results anticipated in Q1 2027. The open-label, single-center investigator-initiated trial also lists overall survival and immune profiling as key secondary/exploratory endpoints (secondary analyses begin ~June 2027), which AIM says could help identify biomarker-defined “super-responder” subsets to inform a potential Phase 3. AIM cites prior named-patient data showing large PFS/OS differences in patients with favorable Neutrophil/Lymphocyte and CA19-9 biomarkers, but those were non-randomized historical comparisons and thus exploratory.
AIM raises ~ $8.5M via warrant exercises and private placements; regains NYSE compliance
AIM ImmunoTech completed a May warrant-exercise inducement (~$3.5M) and two concurrent private placements/issuances on May 21 (~$2.4M) and June 10 (~$2.6M), raising aggregate gross proceeds of roughly $8.5M and issuing ~10.07M common shares plus pre-funded and Class I/J warrants. The company says these transactions restored stockholders' equity above the NYSE American $6.0M minimum, so the '.BC' noncompliance indicator will be removed; however the financings created a material warrant overhang (new warrants convertible into ~27.04M shares). Timing: Same-day dilution is possible if holders convert, but the press release does not provide a firm first-dilution date.
AIM raises ~$2.65M via registered direct + concurrent private placement; 5.11M shares and warrants for 10.22M shares
AIM entered into definitive agreements for a registered direct offering and a concurrent private placement priced at-the-market for gross proceeds of approximately $2.65M, selling 2,554,119 registered shares at $0.5189 and 2,554,119 unregistered shares (or pre-funded warrants) at the same price. The deal also includes unregistered Class J warrants to purchase up to 10,216,476 shares at $0.5189 (5‐year term), the offering is expected to close on or about June 10, 2026, and the Class J warrants are exercisable only subject to stockholder approval. Timing: The press release does not indicate dilution today. Earliest dilution: Jun 10, 2026 settlement.
S-1: Selling holders register 31.3M warrant-backed shares (major potential overhang)
AIM ImmunoTech Inc. filed SEC Form S-1. the 24,328,623 shares outstanding as of May 29, 2026. The company will not receive proceeds from any resale by the selling stockholders, but would receive roughly $14.5 million if all underlying warrants were exercised for cash. Sales and dilution are not immediate — the registration must become effective before resales, and the Class I warrants are not exercisable until the Company obtains the required stockholder approval (they expire five years after the Stockholder Approval Date).
AIM reports final enrollment in Phase 2 Ampligen + Imfinzi pancreatic cancer trial; Dec 2026 CBR readout planned
AIM ImmunoTech says the DURIPANC Phase 2 trial of Ampligen (rintatolimod) plus AstraZeneca's durvalumab has enrolled its final patient (subject to disqualifying pre-treatment issues) and remains on track for a planned December 2026 evaluation of the primary endpoint: Clinical Benefit Rate (CBR) at 6 months. The investigator-initiated, open-label, single-center Phase 2 will enroll up to ~25 subjects and is a joint effort with AstraZeneca and Erasmus Medical Center. No efficacy data from DURIPANC were reported yet; AIM cites prior 57-patient named-patient program data showing longer median survival versus historical controls but those results are non-randomized and require confirmation in larger trials.
AIM releases investor video citing Ampligen preclinical 100% survival in Ebola mouse model
AIM filed SEC Form 8-K. The company highlights Ampligen's TLR3 immune‐modulating mechanism and orphan drug designations from the FDA and EMA, but explicitly states that significant additional human clinical testing and regulatory steps are required and that efficacy in humans is unproven and uncertain.
AIM says Ampligen gave 100% survival in USAMRIID mouse Ebola study; investor video planned
AIM ImmunoTech announced an on-demand investor presentation (June 4) highlighting previously published USAMRIID BSL‐4 preclinical data showing Ampligen (rintatolimod) produced 100% survival when administered early in a lethal mouse Ebola model at 6 mg/kg. The company cited the WHO PHEIC for the Bundibugyo outbreak and highlighted Ampligen's TLR3 mechanism and prior orphan-drug designations, but these results are preclinical, no human Ebola trials or approvals were announced, and human efficacy remains unproven.
AIM says Ampligen gave 100% survival in USAMRIID Ebola mouse study; investor video June 4
AIM ImmunoTech will publish an on‐demand investor presentation on June 4 highlighting a previously published USAMRIID BSL‐4 preclinical study where Ampligen (rintatolimod) produced 100% survival with early dosing in a lethal Ebola mouse model. The company frames this as relevant amid a WHO-declared Bundibugyo outbreak and notes Ampligen's TLR3-based mechanism and existing orphan drug designations, but the result is preclinical and no new human data or clinical trial starts were announced.